While exploring Paradise Island, you might notice glowing rifts indicating tears in space and time. If you jump into one, you ...
Closed financing of up to $50 million; initial tranche of $30 million provides runway through 2027Hosted key opinion leader event highlighting ...
Swave Photonics, the true holographic display company, today announced that its Holographic eXtended Reality (HXR) Spatial ...
Phase 1b data demonstrating favorable safety and tolerability profile and potent reductions in viral nucleic acids highlighted in late-breaking ...
Axsome obtains exclusive global rights to AZD7325, a novel oral selective GABAA α2,3 receptor positive allosteric modulator ...
These 52-week data reinforce HTD1801's potential as a truly differentiated therapeutic to concurrently address metabolic ...
MedPage Today on MSN
Psych Telehealth Prescribing Extension; Jennifer Lawrence's PPD; Youth Turn to AI
A second dose of an investigational nasal spray formulation of mebufotenin benzoate -- a tryptamine psychedelic -- offered ...
The U.S. FDA has granted orphan drug designation to Dewpoint Therapeutics Inc.’s DPTX-3186, its first-in-class condensate ...
US biotech Dewpoint Therapeutics has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to DPTX3186, its first-in-class condensate modulator for the ...
ObesityWeek 2025, held in Atlanta from November 4-7, showcased unprecedented clinical data that signals a fundamental shift in the obesity treatment landscape. The most striking breakthrough at ...
As Neuphoria Therapeutics considers its options in the wake of the failure of its phase 3 social anxiety program, an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback